4 results about "Fatty Acid Synthases" patented technology

This invention belongs to the field of biomedical technology, specifically relating to a compound extracted from *Acer buergerianum* (a type of shrub), its extraction method, and its application in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease. This invention is the first to obtain a natural compound with a novel structure from *Acer buergerianum*, and provides a method for its preparation. Activity studies were conducted, and experimental data show that the compound exhibits low cytotoxicity and no significant cytotoxicity to normal cells. It can inhibit the expression of fatty acid synthases ACC, ACLY, and FAS, thereby inhibiting de novo fatty acid synthesis in cells, suppressing lipid droplet accumulation, and reducing cellular lipid levels. This compound has broad application prospects in the preparation of drugs for the prevention or treatment of non-alcoholic fatty liver disease.

This invention discloses a 2,6,10,14-tetramethylpentadecane derivative compound, its preparation method, and its applications. The structure of the compound is shown in formula (I). Compared with natural 2,6,10,14-tetramethylpentadecane, the compound has significantly enhanced binding ability to the malonyl / acetyltransferase functional domain (MAT) of fatty acid synthase (FASN), significantly enhanced ability to inhibit fatty acid synthesis, significantly enhanced therapeutic effect on diseases related to FASN abnormalities, significantly enhanced activation of anti-tumor immunity, and significantly enhanced inhibition of tumor growth. It can be effectively used in the preparation of drugs that inhibit fatty acid synthesis, drugs that treat fatty acid synthesis abnormalities, cancer treatment drugs, and immunotherapy drugs.

This invention discloses the application of verbascoside in the preparation of drugs for treating obesity and related metabolic disorders, relating to the field of biopharmaceuticals. The drug upregulates the expression of phosphorylated AMP-activated protein kinase α and carnitine palmitoyltransferase-1α, while downregulating the expression of sterol regulatory element-binding protein-1c, fatty acid synthase, and acetyl-CoA carboxylase. This application is the first systematic study of the comprehensive intervention effect of verbascoside on diet-induced obesity and related metabolic disorders. In an in vivo obese mouse model, it was demonstrated that verbascoside can significantly inhibit excessive weight gain induced by a high-fat diet, reduce fasting blood glucose and fasting insulin levels, improve dyslipidemia indicators including triglycerides, total cholesterol, non-esterified fatty acids, and low-density lipoprotein cholesterol, enhance insulin sensitivity, and alleviate macrovesicular steatosis and hepatocellular damage.

Provided herein are pharmaceutical compositions that include a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof. Also included herein is a method of regulating a disease governed by Fatty Acid Synthase (FAS) in a subject in need thereof, including atheroprogression and PAD.